Abstract:Cellular senescence is a form of proliferative arrest triggered in response to a wide variety of stimuli and characterized by unique changes in cell morphology and function. Although unable to divide, senescent cells remain metabolically active and acquire the ability to produce and secrete bioactive molecules, some of which have recognized pro-inflammatory and/or pro-tumorigenic actions. As expected, this “senescence-associated secretory phenotype (SASP)” accounts for most of the non-cell-autonomous effects of senescent cells, which can be beneficial or detrimental for tissue homeostasis, depending on the context. It is now evident that many features linked to cellular senescence, including the SASP, reflect complex changes in the activities of mTOR and other metabolic pathways. Indeed, the available evidence indicates that mTOR-dependent signaling is required for the maintenance or implementation of different aspects of cellular senescence. Thus, depending on the cell type and biological context, inhibiting mTOR in cells undergoing senescence can reverse senescence, induce quiescence or cell death, or exacerbate some features of senescent cells while inhibiting others. Interestingly, autophagy—a highly regulated catabolic process—is also commonly upregulated in senescent cells. As mTOR activation leads to repression of autophagy in non-senescent cells (mTOR as an upstream regulator of autophagy), the upregulation of autophagy observed in senescent cells must take place in an mTOR-independent manner. Notably, there is evidence that autophagy provides free amino acids that feed the mTOR complex 1 (mTORC1), which in turn is required to initiate the synthesis of SASP components. Therefore, mTOR activation can follow the induction of autophagy in senescent cells (mTOR as a downstream effector of autophagy). These functional connections suggest the existence of autophagy regulatory pathways in senescent cells that differ from those activated in non-senescence contexts. We envision that untangling these functional connections will be key for the generation of combinatorial anti-cancer therapies involving pro-senescence drugs, mTOR inhibitors, and/or autophagy inhibitors.

mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype

MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation

Erratum: mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype

mTOR Activity and Autophagy in Senescent Cells, a Complex Partnership

Persistent mTORC1 signaling in cell senescence results from defects in amino acid and growth factor sensing

mTORC2: A neglected player in aging regulation

The mTORC1-autophagy pathway is a target for senescent cell elimination

mTORC2 Is the Major Second Layer Kinase Negatively Regulating FOXO3 Activity

The Mtor–s6k Pathway Links Growth Signalling to DNA Damage Response by Targeting RNF168

Coupling shRNA screens with single-cell RNA-seq identifies a dual role for mTOR in reprogramming-induced senescence

Redox and mTOR-dependent regulation of plasma lamellar calcium influx controls the senescence-associated secretory phenotype

Hypothalamic Mtorc2 is Essential for Metabolic Health and Longevity

KLHL22 Activates Amino-Acid-dependent Mtorc1 Signalling to Promote Tumorigenesis and Ageing.

Author Correction: MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation

Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process

The mTOR–lysosome axis at the centre of ageing

mTOR and Aging: An Old Fashioned Dress

Targeting mTOR for Anti-Aging and Anti-Cancer Therapy

mTORC2 facilitates endothelial cell senescence by suppressing Nrf2 expression via the Akt/GSK-3β/C/EBPα signaling pathway

Mtor Signaling in Cardiometabolic Disease, Cancer, and Aging

Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor